# CART84

Source: https://onco.cc/drugs/cart84/  
OnCo record `cart84` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CART84 is an experimental CAR-T cell therapy from Gyala Therapeutics in phase 2 trials for acute myeloid leukaemia, aimed at CD3.

## Summary

CART84 is a CAR-T cell therapy developed by Gyala Therapeutics. Its target is CD3 (the sponsor names CD84). The sponsor states: Autologous T cells transduced with a lentiviral vector expressing an anti-CD84 chimeric antigen receptor, to recognise and kill CD84-expressing leukaemia cells. ClinicalTrials.gov describes the intervention as: GYA01 (CART84): autologous cell-based product containing CD3+ T cells transduced with a lentiviral vector expressing an anti-CD84 chimeric antigen receptor (CAR). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in acute myeloid leukaemia. The largest, NCT07471789, plans to enrol 33 participants with primary completion expected 2029-05-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: CAR-T cell therapy
- Mechanism: Autologous T cells transduced with a lentiviral vector expressing an anti-CD84 chimeric antigen receptor, to recognise and kill CD84-expressing leukaemia cells.

## Sources

- ClinicalTrials.gov: trials of CART84: https://clinicaltrials.gov/search?intr=CART84

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- targets: [CD3](https://onco.cc/targets/cd3/)
- trials: [Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).](https://onco.cc/trials/nct07471789/)

---
JSON: https://onco.cc/api/v1/entities/cart84.json